Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
Epilepsy; Seizure
About this trial
This is an interventional treatment trial for Epilepsy; Seizure
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis of epilepsy. For the purpose of inclusion, the seizure types include complex partial, simple partial motor, primary generalized tonic-clonic, secondary generalized tonic-clonic, tonic, clonic and atonic seizures, as well as simple partial and absence seizures. Stable treatment regimen with no change in antiepileptic drugs or antiepileptic drug doses for 28 days prior to enrollment. Women of childbearing potential must be using a standard method of birth control and agree not to become pregnant during the trial. Men must agree to not father a child during the trial. BMI must be between 18 and 35. Exclusion Criteria: Occurrence of non-epileptic psychogenic spells within 2 years prior to enrollment. Current or past history of diabetes or any abnormality of glucose metabolism. Use of glucocorticoids, hypoglycemic agents (e.g. metformin) or any drug that alters glucose levels. Use of any drug that is expected to alter glucose absorption, metabolism or serum measurements. Clinically significant psychiatric or medical disease. Previous therapeutic use of 2DG. Pregnant or nursing women. Use of an investigational medication within 2 months prior to enrollment. Supine systolic blood pressure < 90 or > 160 mm Hg or diastolic > 90 mm Hg, or pulse < 60 or > 110 BPM. Clinically significant abnormal 12-lead ECG. Baseline prolongation of the QTc interval > 450 msec. Clinically significant abnormal result by speckle tracking echocardiography (STE). Elevated ALT or AST more than 1.5 times upper reference limit. Baseline fasting glucose < 60 or > 110. History of status epilepticus within 6 months prior to enrollment. Progressive structural brain lesion or illness likely to progress during the study.
Sites / Locations
- University of Virginia School of MedicineRecruiting
Arms of the Study
Arm 1
Experimental
Sequential ascending dose cohort
Cohort 1 will receive single 40 mg dose once. Cohort 2 will receive single 60 mg dose once. Cohort 3 will receive (2) 60 mg dose on one occasion.